Profile of Gary Allenby
Gary Allenby (GA), Senior Director of Biology at Charnwood Molecular, is a 30-year veteran of pre-clinical drug discovery and an entrepreneur. Following a Ph.D. between the Medical Research Council and I.C.I., his industrial career began at Hoffmann La Roche in the U.S.A. working on the toxicity of retinoids. In 1995 he joined Glaxo Smith Kline in the U.K., developing bioassays for ion channel drug discovery and automating cell-based assays for high throughput screening. In 2000 he joined AstraZeneca (AZ), developing bioassays for respiratory and inflammatory disease targets and managing a team of several bio-scientists. In 2011 he left AZ and was one of three founding entrepreneurs of Aurelia Bioscience, a biology based Contract Research Organisation (CRO). He helped build the business from scratch and in 2021, Aurelia Bioscience was acquired by Charnwood Molecular, a chemistry-based CRO, to form an integrated drug discovery company. Now with a group of 20 Ph.D. drug discovery scientists, his focus is on the development of drug discovery screening cascades for clients, in addition to the development and implementation of new and advanced technologies for the study of biology and their application to client projects.